Press release
Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally
Portfolio includes Dexcom G7, Dexcom ONE and Dexcom G6 and offers the most powerful, easy to use, connected and covered CGM options for people living with
About this update from Dexcom, Inc.
[{"type":"text","content":"\n\nPortfolio includes Dexcom G7, Dexcom ONE and Dexcom G6 and offers the most powerful, easy to use, connected and covered CGM options for people living with diabetes around the world.\n\n\nThe portfolio is built on the unparalleled accuracy of Dexcom CGM,1 supported by more peer reviewed research than any other CGM system on the market.\n\n\nATTD conference symposia, posters and presentations continue to affirm the use of Dexcom CGM is central to optimal diabetes management when compared to fingersticks and intermittently scanned CGM.\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nDexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the strength of its CGM portfolio and unveil new clinical and real-world evidence that continues to demonstrate the effectiveness of Dexcom CGM at the 16th International Conference on Advanced Technologies and Treatments for Diabetes held Feb. 22-25, 2023 in Berlin.\n\n“Last year at ATTD we first introduced our expanded portfolio of Dexcom CGM systems,” said Jake Leach, executive vice president and chief operating officer of Dexcom. “Almost one year later we are thrilled to report that Dexcom G7 is already available in eight countries, Dexcom ONE has played a significant role in helping expand CGM coverage for millions more people with diabetes and Dexcom G6 continues to lead the industry in connectivity with automated insulin delivery systems and digital health apps.”\n\nDexcom G7, the most powerful and simple CGM, is now available in the United States, Germany, the United Kingdom, Ireland, Austria, Hong Kong, New Zealand and South Africa with additional launches planned in 2023. Feedback from initial Dexcom G7 users has been extremely positive, with consistent praise for the 60% smaller wearable,* shortest warmup period on the market† and more engaging and consumer-friendly mobile app. In addition, 97% of initial users surveyed found Dexcom G7 easy to use.2\n\nDexcom ONE continues to help expand access to CGM globally by providing a simple and accurate‡,3 option to meet the diverse needs of customers, clinicians, and payers around the world. This has been a key element of the company’s global access initiatives, which expanded reimbursed coverage to Dexcom CGM outside the US by more than 3.5 million lives over the past 18 mon...